Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer
- 30 October 2018
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (4) , 454-459
Abstract
Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.Keywords
This publication has 16 references indexed in Scilit:
- Chemotherapy near the end of life: a retrospective single-centre analysis of patients’ chartsBMC Palliative Care, 2014
- Palliative chemotherapy during the last month of lifeAnnals of Oncology, 2011
- Nutritional predictors of postoperative outcome in pancreatic cancerBritish Journal of Surgery, 2010
- Prognostic nutritional Index: A tool to predict the biological aggressiveness of gastric carcinomaSurgery Today, 2010
- Use of chemotherapy at end of life in oncology patientsAnnals of Oncology, 2009
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyJournal of Clinical Oncology, 2009
- The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysisPsycho-Oncology, 2007
- Development of a Clinical Guideline for Palliative Sedation Therapy Using the Delphi MethodJournal of Palliative Medicine, 2005
- Trends in the Aggressiveness of Cancer Care Near the End of LifeJournal of Clinical Oncology, 2004
- Clarifying Confusion: The Confusion Assessment MethodAnnals of Internal Medicine, 1990